1
|
Akintunde JK, Falomo IM, Akinbohun OM, Erinoso SO, Ugwor E, Folayan AD, Ateate AD. Naringin corrects renal failure related to Lesch-Nyhan disease in a rat model via NOS-cAMP-PKA and BDNF/TrkB pathways. J Biochem Mol Toxicol 2024; 38:e23558. [PMID: 37865952 DOI: 10.1002/jbt.23558] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2022] [Revised: 09/11/2023] [Accepted: 10/02/2023] [Indexed: 10/24/2023]
Abstract
This study explored the effect of naringin (NAR) on HGPRT1 deficiency and hyperuricemia through NOS-cAMP-PKA and BDNF/TrkB signaling pathways induced by caffeine (CAF) and KBrO3 in a rat model. Sixty-three adult male albino rats were randomly assigned into nine (n = 7) groups. Group I: control animals, Group II was treated with 100 mg/kg KBrO3 , Group III was treated with 250 mg/kg CAF, Group IV was treated with 100 mg/kg KBrO3 + 250 mg/kg CAF, Group V was administered with 100 mg/kg KBrO3 + 100 mg/kg haloperidol, Group VI was administered with 100 mg/kg KBrO3 + 50 mg/kg NAR, Group VII was administered with 500 mg/kg CAF + 50 mg/kg NAR, and Group VIII was administered with 100 mg/kg KBrO3 + 250 mg/kg CAF + 50 mg/kg NAR. Finally, group IX was treated with 50 mg/kg NAR. The exposure of rats to KBrO3 and CAF for 21 days induced renal dysfunction linked with Lesch-Nyhan disease. NAR obliterated renal dysfunction linked with Lesch-Nyhan disease by decreasing uric acid, renal malondialdehyde level, inhibiting the activities of arginase, and phosphodiesterase-51 (PDE-51) with corresponding upregulation of brain derived-neurotrophic factor and its receptor (BDNF-TrkB), Bcl11b, HGPRT1, and DARPP-32. Additionally, renal failure related to Lesch-Nyhan disease was remarkably corrected by NAR as shown by the reduced activities of AChE and enzymes of ATP hydrolysis (ATPase, AMPase, and ADA) with affiliated increase in the NO level. This study therefore validates NAR as nontoxic and effective chemotherapy against kidney-related Lesch-Nyhan disease by mitigating effects of toxic food additives and enzymes of ATP-hydrolysis via NOS-cAMP-PKA and BDNF/TrkB signaling pathways.
Collapse
Affiliation(s)
- Jacob K Akintunde
- Molecular Toxicology and Biomedical Research Group, Department of Biochemistry, College of Biosciences, Federal University of Agriculture, Abeokuta, Nigeria
| | - Idowu M Falomo
- Molecular Toxicology and Biomedical Research Group, Department of Biochemistry, College of Biosciences, Federal University of Agriculture, Abeokuta, Nigeria
| | - Oreoluwa M Akinbohun
- Molecular Toxicology and Biomedical Research Group, Department of Biochemistry, College of Biosciences, Federal University of Agriculture, Abeokuta, Nigeria
| | - S O Erinoso
- Molecular Toxicology and Biomedical Research Group, Department of Biochemistry, College of Biosciences, Federal University of Agriculture, Abeokuta, Nigeria
| | - Emmanuel Ugwor
- Molecular Toxicology and Biomedical Research Group, Department of Biochemistry, College of Biosciences, Federal University of Agriculture, Abeokuta, Nigeria
| | - Adeniyi D Folayan
- Molecular Toxicology and Biomedical Research Group, Department of Biochemistry, College of Biosciences, Federal University of Agriculture, Abeokuta, Nigeria
| | - A D Ateate
- Molecular Toxicology and Biomedical Research Group, Department of Biochemistry, College of Biosciences, Federal University of Agriculture, Abeokuta, Nigeria
| |
Collapse
|
2
|
Camici M, Garcia-Gil M, Allegrini S, Pesi R, Bernardini G, Micheli V, Tozzi MG. Inborn Errors of Purine Salvage and Catabolism. Metabolites 2023; 13:787. [PMID: 37512494 PMCID: PMC10383617 DOI: 10.3390/metabo13070787] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2023] [Revised: 06/20/2023] [Accepted: 06/21/2023] [Indexed: 07/30/2023] Open
Abstract
Cellular purine nucleotides derive mainly from de novo synthesis or nucleic acid turnover and, only marginally, from dietary intake. They are subjected to catabolism, eventually forming uric acid in humans, while bases and nucleosides may be converted back to nucleotides through the salvage pathways. Inborn errors of the purine salvage pathway and catabolism have been described by several researchers and are usually referred to as rare diseases. Since purine compounds play a fundamental role, it is not surprising that their dysmetabolism is accompanied by devastating symptoms. Nevertheless, some of these manifestations are unexpected and, so far, have no explanation or therapy. Herein, we describe several known inborn errors of purine metabolism, highlighting their unexplained pathological aspects. Our intent is to offer new points of view on this topic and suggest diagnostic tools that may possibly indicate to clinicians that the inborn errors of purine metabolism may not be very rare diseases after all.
Collapse
Affiliation(s)
- Marcella Camici
- Unità di Biochimica, Dipartimento di Biologia, Università di Pisa, Via San Zeno 51, 56127 Pisa, Italy
| | - Mercedes Garcia-Gil
- Unità di Fisiologia Generale, Dipartimento di Biologia, Università di Pisa, Via San Zeno 31, 56127 Pisa, Italy
- CISUP, Centro per l'Integrazione Della Strumentazione Dell'Università di Pisa, 56127 Pisa, Italy
- Centro di Ricerca Interdipartimentale Nutrafood "Nutraceuticals and Food for Health", Università di Pisa, 56126 Pisa, Italy
| | - Simone Allegrini
- Unità di Biochimica, Dipartimento di Biologia, Università di Pisa, Via San Zeno 51, 56127 Pisa, Italy
- CISUP, Centro per l'Integrazione Della Strumentazione Dell'Università di Pisa, 56127 Pisa, Italy
- Centro di Ricerca Interdipartimentale Nutrafood "Nutraceuticals and Food for Health", Università di Pisa, 56126 Pisa, Italy
| | - Rossana Pesi
- Unità di Biochimica, Dipartimento di Biologia, Università di Pisa, Via San Zeno 51, 56127 Pisa, Italy
| | - Giulia Bernardini
- Dipartimento di Biotecnologie, Chimica e Farmacia, Università di Siena, Via A. Moro 2, 53100 Siena, Italy
| | - Vanna Micheli
- Dipartimento di Biotecnologie, Chimica e Farmacia, Università di Siena, Via A. Moro 2, 53100 Siena, Italy
- LND Famiglie Italiane ODV-Via Giovanetti 15-20, 16149 Genova, Italy
| | - Maria Grazia Tozzi
- Unità di Biochimica, Dipartimento di Biologia, Università di Pisa, Via San Zeno 51, 56127 Pisa, Italy
| |
Collapse
|
3
|
Akintunde JK, Abinu OS, Taiwo KF, Sodiq RA, Folayan AD, Ate AD. Disorders of Hippocampus Facilitated by Hypertension in Purine Metabolism Deficiency is Repressed by Naringin, a Bi-flavonoid in a Rat Model via NOS/cAMP/PKA and DARPP-32, BDNF/TrkB Pathways. Neurotox Res 2022; 40:2148-2166. [PMID: 36098940 DOI: 10.1007/s12640-022-00578-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2022] [Revised: 06/27/2022] [Accepted: 09/02/2022] [Indexed: 01/04/2023]
Abstract
Individuals who are hypertensive have a higher tendency of predisposition to other genetic diseases including purine metabolism deficiency. Therefore, the search for nontoxic and effective chemo protective agents to abrogate hypertension-mediated genetic disease is vital. This study therefore investigated the repressive effect of naringin (NAR) against disorder of hippocampus facilitated by hypertension in purine metabolism deficiency. Male albino rats randomly assigned into nine groups (n = 7) were treated for 35 days. Group I: control animals, Group II was treated with 100 mg/kg KBrO3, Group III was treated with 250 mg/kg caffeine, and Group IV was treated with 100 mg/kg KBrO3 + 250 mg/kg caffeine. Group V was administered with 100 mg/kg KBrO3 + 100 mg/kg haloperidol. Group VI was administered with 100 mg/kg KBrO3 + 50 mg/kg NAR. Group VII was administered with 250 mg/kg caffeine + 50 mg/kg NAR, and Group VIII was administered with 100 mg/kg KBrO3 + 250 mg/kg caffeine + 50 mg/kg NAR. Finally, group IX was treated with 50 mg/kg NAR. The sub-acute exposure to KBrO3 and CAF induced hypertension and mediated impairment in the hippocampus cells. This was apparent by the increase in PDE-51, arginase, and enzymes of ATP hydrolysis (ATPase and AMPase) with a simultaneous increase in cholinergic (AChE and BuChE) and adenosinergic (ADA) enzymes. The hypertensive-mediated hippocampal impairment was associated to alteration of NO and AC signaling coupled with lower expression of brain-derived neurotrophic factor and its receptor (BDNF-TrkB), down regulation of Bcl11b and DARPP-32 which are neurodevelopmental proteins, and hypoxanthine accumulation. However, these features of CAF-mediated hippocampal damage in KBrO3-induced hypertensive rats were repressed by post-treatment with NAR via production of neuro-inflammatory mediators, attenuation of biochemical alterations, stabilizing neurotransmitter enzymes, regulating NOS/cAMP/PKA and DARPP-32, BDNF/TrkB signaling, and restoring hippocampal tissues.
Collapse
Affiliation(s)
- J K Akintunde
- Applied Biochemistry and Molecular Toxicology Research Group, Department of Biochemistry, College of Biosciences, Federal University of Agriculture, Abeokuta, Nigeria.
| | - O S Abinu
- Applied Biochemistry and Molecular Toxicology Research Group, Department of Biochemistry, College of Biosciences, Federal University of Agriculture, Abeokuta, Nigeria
| | - K F Taiwo
- Applied Biochemistry and Molecular Toxicology Research Group, Department of Biochemistry, College of Biosciences, Federal University of Agriculture, Abeokuta, Nigeria
| | - R A Sodiq
- Applied Biochemistry and Molecular Toxicology Research Group, Department of Biochemistry, College of Biosciences, Federal University of Agriculture, Abeokuta, Nigeria
| | - A D Folayan
- Applied Biochemistry and Molecular Toxicology Research Group, Department of Biochemistry, College of Biosciences, Federal University of Agriculture, Abeokuta, Nigeria
| | - A D Ate
- Applied Biochemistry and Molecular Toxicology Research Group, Department of Biochemistry, College of Biosciences, Federal University of Agriculture, Abeokuta, Nigeria
| |
Collapse
|
4
|
PDE10A mutations help to unwrap the neurobiology of hyperkinetic disorders. Cell Signal 2019; 60:31-38. [PMID: 30951862 DOI: 10.1016/j.cellsig.2019.04.001] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2019] [Revised: 03/31/2019] [Accepted: 04/01/2019] [Indexed: 12/31/2022]
Abstract
The dual-specific cAMP/cGMP phosphodiesterase PDE10A is exclusively localised to regions of the brain and specific cell types that control crucial brain circuits and behaviours. The downside to this expression pattern is that PDE10A is also positioned to be a key player in pathology when its function is perturbed. The last decade of research has seen a clear role emerge for PDE10A inhibition in modifying behaviours in animal models of psychosis and Huntington's disease. Unfortunately, this has not translated to the human diseases as expected. More recently, a series of families with hyperkinetic movement disorders have been identified with mutations altering the PDE10A protein sequence. As these mutations have been analysed and characterised in other model systems, we are beginning to learn more about PDE10A function and perhaps catch a glimpse into how PDE10A activity could be modified for therapeutic benefit.
Collapse
|
5
|
Zhang Y, Gao B, Zheng F, Lu S, Li Y, Xiong Y, Yang Q, Yang Y, Fu P, Xiao F, Wang X. The Phosphodiesterase 10A Inhibitor PF-2545920 Enhances Hippocampal Excitability and Seizure Activity Involving the Upregulation of GluA1 and NR2A in Post-synaptic Densities. Front Mol Neurosci 2017; 10:100. [PMID: 28439226 PMCID: PMC5383654 DOI: 10.3389/fnmol.2017.00100] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2016] [Accepted: 03/23/2017] [Indexed: 12/16/2022] Open
Abstract
Phosphodiesterase regulates the homeostasis of cAMP and cGMP, which increase the strength of excitatory neural circuits and/or decrease inhibitory synaptic plasticity. Abnormally, synchronized synaptic transmission in the brain leads to seizures. A phosphodiesterase 10A (PDE10A) inhibitor PF-2545920 has recently attracted attention as a potential therapy for neurological and psychiatric disorders. We hypothesized that PF-2545920 plays an important role in status epilepticus (SE) and investigated the underlying mechanisms. PDE10A was primarily located in neurons, and PDE10A expression increased significantly in patients with temporal lobe epilepsy. PF-2545920 enhanced the hyperexcitability of pyramidal neurons in rat CA1, as measured by the frequency of action potentials and miniature excitatory post-synaptic current. GluA1 and NR2A expression also increased significantly in post-synaptic densities, with or without SE in rats treated with PF-2545920. The ratio of p-GluA1/GluA1 increased in the presence of PF-2545920 in groups with SE. Our results suggest that PF-2545920 facilitates seizure activity via the intracellular redistribution of GluA1 and NR2A in the hippocampus. The upregulation of p-GluA1 may play an important role in trafficking GluA1 to post-synaptic densities. The data suggest it would be detrimental to use the drug in seizure patients and might cause neuronal hyperexcitability in non-epileptic individuals.
Collapse
Affiliation(s)
- Yanke Zhang
- Department of Neurology, The First Affiliated Hospital of Chongqing Medical UniversityChongqing, China
| | - Baobing Gao
- Department of Neurology, Chongqing General HospitalChongqing, China
| | - Fangshuo Zheng
- Department of Neurology, The First Affiliated Hospital of Chongqing Medical UniversityChongqing, China
| | - Shanshan Lu
- Department of Neurology, The First Affiliated Hospital of Chongqing Medical UniversityChongqing, China
| | - Yun Li
- Department of Neurology, The First Affiliated Hospital of Chongqing Medical UniversityChongqing, China
| | - Yan Xiong
- Department of Neurology, The First Affiliated Hospital of Chongqing Medical UniversityChongqing, China
| | - Qin Yang
- Department of Neurology, The First Affiliated Hospital of Chongqing Medical UniversityChongqing, China
| | - Yong Yang
- Department of Neurology, The First Affiliated Hospital of Chongqing Medical UniversityChongqing, China
| | - Pengfei Fu
- Department of Neurology, The First Affiliated Hospital of Chongqing Medical UniversityChongqing, China
| | - Fei Xiao
- Department of Neurology, The First Affiliated Hospital of Chongqing Medical UniversityChongqing, China
| | - Xuefeng Wang
- Department of Neurology, The First Affiliated Hospital of Chongqing Medical UniversityChongqing, China.,Center of Epilepsy, Beijing Institute for Brain DisordersBeijing, China.,Chongqing Key Laboratory of NeurologyChongqing, China
| |
Collapse
|
6
|
Meek S, Thomson AJ, Sutherland L, Sharp MGF, Thomson J, Bishop V, Meddle SL, Gloaguen Y, Weidt S, Singh-Dolt K, Buehr M, Brown HK, Gill AC, Burdon T. Reduced levels of dopamine and altered metabolism in brains of HPRT knock-out rats: a new rodent model of Lesch-Nyhan Disease. Sci Rep 2016; 6:25592. [PMID: 27185277 PMCID: PMC4869022 DOI: 10.1038/srep25592] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2016] [Accepted: 04/19/2016] [Indexed: 02/07/2023] Open
Abstract
Lesch-Nyhan disease (LND) is a severe neurological disorder caused by loss-of-function mutations in the gene encoding hypoxanthine phosphoribosyltransferase (HPRT), an enzyme required for efficient recycling of purine nucleotides. Although this biochemical defect reconfigures purine metabolism and leads to elevated levels of the breakdown product urea, it remains unclear exactly how loss of HPRT activity disrupts brain function. As the rat is the preferred rodent experimental model for studying neurobiology and diseases of the brain, we used genetically-modified embryonic stem cells to generate an HPRT knock-out rat. Male HPRT-deficient rats were viable, fertile and displayed normal caged behaviour. However, metabolomic analysis revealed changes in brain biochemistry consistent with disruption of purine recycling and nucleotide metabolism. Broader changes in brain biochemistry were also indicated by increased levels of the core metabolite citrate and reduced levels of lipids and fatty acids. Targeted MS/MS analysis identified reduced levels of dopamine in the brains of HPRT-deficient animals, consistent with deficits noted previously in human LND patients and HPRT knock-out mice. The HPRT-deficient rat therefore provides a new experimental platform for future investigation of how HPRT activity and disruption of purine metabolism affects neural function and behaviour.
Collapse
Affiliation(s)
- Stephen Meek
- The Roslin Institute and R(D)VS, University of Edinburgh, Easter Bush, Midlothian, EH25 9RG, Scotland
| | - Alison J. Thomson
- The Roslin Institute and R(D)VS, University of Edinburgh, Easter Bush, Midlothian, EH25 9RG, Scotland
| | - Linda Sutherland
- The Roslin Institute and R(D)VS, University of Edinburgh, Easter Bush, Midlothian, EH25 9RG, Scotland
| | - Matthew G. F. Sharp
- Central Bioresearch Services, University of Edinburgh, Chancellor’s Building, 49 Little France Crescent, Edinburgh EH16 4SB, Scotland
| | - Julie Thomson
- Central Bioresearch Services, University of Edinburgh, Chancellor’s Building, 49 Little France Crescent, Edinburgh EH16 4SB, Scotland
| | - Valerie Bishop
- The Roslin Institute and R(D)VS, University of Edinburgh, Easter Bush, Midlothian, EH25 9RG, Scotland
| | - Simone L. Meddle
- The Roslin Institute and R(D)VS, University of Edinburgh, Easter Bush, Midlothian, EH25 9RG, Scotland
| | - Yoann Gloaguen
- Glasgow Polyomics, College of Medical, Veterinary and Life Sciences, University of Glasgow, Wolfson Wohl Cancer Research Centre, Garscube Campus, Bearsden, G61 1QH, Scotland
| | - Stefan Weidt
- Glasgow Polyomics, College of Medical, Veterinary and Life Sciences, University of Glasgow, Wolfson Wohl Cancer Research Centre, Garscube Campus, Bearsden, G61 1QH, Scotland
| | - Karamjit Singh-Dolt
- The Roslin Institute and R(D)VS, University of Edinburgh, Easter Bush, Midlothian, EH25 9RG, Scotland
| | - Mia Buehr
- The Roslin Institute and R(D)VS, University of Edinburgh, Easter Bush, Midlothian, EH25 9RG, Scotland
| | - Helen K. Brown
- The Roslin Institute and R(D)VS, University of Edinburgh, Easter Bush, Midlothian, EH25 9RG, Scotland
| | - Andrew C. Gill
- The Roslin Institute and R(D)VS, University of Edinburgh, Easter Bush, Midlothian, EH25 9RG, Scotland,
| | - Tom Burdon
- The Roslin Institute and R(D)VS, University of Edinburgh, Easter Bush, Midlothian, EH25 9RG, Scotland,
| |
Collapse
|
7
|
Cell fate determination, neuronal maintenance and disease state: The emerging role of transcription factors Lmx1a and Lmx1b. FEBS Lett 2015; 589:3727-38. [PMID: 26526610 DOI: 10.1016/j.febslet.2015.10.020] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2015] [Revised: 10/06/2015] [Accepted: 10/15/2015] [Indexed: 01/28/2023]
Abstract
LIM-homeodomain (LIM-HD) proteins are evolutionary conserved developmental transcription factors. LIM-HD Lmx1a and Lmx1b orchestrate complex temporal and spatial gene expression of the dopaminergic pathway, and evidence shows they are also involved in adult neuronal homeostasis. In this review, the multiple roles played by Lmx1a and Lmx1b will be discussed. Controlled Lmx1a and Lmx1b expression and activities ensure the proper formation of critical signaling centers, including the embryonic ventral mesencephalon floor plate and sharp boundaries between lineage-specific cells. Lmx1a and Lmx1b expression persists in mature dopaminergic neurons of the substantia nigra pars compacta and the ventral tegmental area, and their role in the adult brain is beginning to be revealed. Notably, LMX1B expression was lower in brain tissue affected by Parkinson's disease. Actual and future applications of Lmx1a and Lmx1b transcription factors in stem cell production as well as in direct conversion of fibroblast into dopaminergic neurons are also discussed. A thorough understanding of the role of LMX1A and LMX1B in a number of disease states, including developmental diseases, cancer and neurodegenerative diseases, could lead to significant benefits for human healthcare.
Collapse
|
8
|
Guibinga GH. MicroRNAs: tools of mechanistic insights and biological therapeutics discovery for the rare neurogenetic syndrome Lesch-Nyhan disease (LND). ADVANCES IN GENETICS 2015; 90:103-131. [PMID: 26296934 DOI: 10.1016/bs.adgen.2015.06.001] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
Abstract
MicroRNAs (miRNAs) are small regulatory RNAs that modulate the translation of mRNA. They have emerged over the past few years as indispensable entities in the transcriptional regulation of genes. Their discovery has added additional layers of complexity to regulatory networks that control cellular homeostasis. Also, their dysregulated pattern of expression is now well demonstrated in myriad diseases and pathogenic processes. In the current review, we highlight the role of miRNAs in Lesch-Nyhan disease (LND), a rare neurogenetic syndrome caused by mutations in the purine metabolic gene encoding the hypoxanthine-guanine phosphoribosyltransferase (HPRT) enzyme. We describe how experimental and biocomputational approaches have helped to unravel genetic and signaling pathways that provide mechanistic understanding of some of the molecular and cellular basis of this ill-defined neurogenetic disorder. Through miRNA-based target predictions, we have identified signaling pathways that may be of significance in guiding biological therapeutic discovery for this incurable neurological disorder. We also propose a model to explain how a gene such as HPRT, mostly known for its housekeeping metabolic functions, can have pleiotropic effects on disparate genes and signal transduction pathways. Our hypothetical model suggests that HPRT mRNA transcripts may be acting as competitive endogenous RNAs (ceRNAs) intertwined in multiregulatory cross talk between key neural transcripts and miRNAs. Overall, this approach of using miRNA-based genomic approaches to elucidate the molecular and cellular basis of LND and guide biological target identification might be applicable to other ill-defined rare inborn-error metabolic diseases.
Collapse
Affiliation(s)
- Ghiabe-Henri Guibinga
- Division of Genetics, Department of Pediatrics, School of Medicine, University of California San Diego, La Jolla, CA, USA.
| |
Collapse
|
9
|
Phosphodiesterase 10A inhibitors: analysis of US/EP patents granted since 2012. Pharm Pat Anal 2015; 4:161-86. [DOI: 10.4155/ppa.15.11] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Phosphodiesterases are enzymes that metabolically inactivate the intracellular second messengers 3′,5′-cyclic adenosine and guanosine monophosphate contributing to the control of multiple biological processes. Among them, PDE10A has the most restricted distribution with high expression in striatal medium spiny neurons. Dysfunction of this key brain circuit has been associated with different psychiatric and neurodegenerative disorders. The unique role of PDE10A, together with its increased pharmacological characterization, have prompted enormous interest in investigating the potential of inhibitors of this enzyme as potential novel therapeutic agents This article reviews PDE10A related patents issued in the period 2012–2014 in the USA and Europe offering also a perspective on potential avenues for the future clinical development of phosphodiesterase 10A inhibitors.
Collapse
|
10
|
Fasullo M, Endres L. Nucleotide salvage deficiencies, DNA damage and neurodegeneration. Int J Mol Sci 2015; 16:9431-49. [PMID: 25923076 PMCID: PMC4463597 DOI: 10.3390/ijms16059431] [Citation(s) in RCA: 66] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2015] [Revised: 03/16/2015] [Accepted: 04/03/2015] [Indexed: 12/20/2022] Open
Abstract
Nucleotide balance is critically important not only in replicating cells but also in quiescent cells. This is especially true in the nervous system, where there is a high demand for adenosine triphosphate (ATP) produced from mitochondria. Mitochondria are particularly prone to oxidative stress-associated DNA damage because nucleotide imbalance can lead to mitochondrial depletion due to low replication fidelity. Failure to maintain nucleotide balance due to genetic defects can result in infantile death; however there is great variability in clinical presentation for particular diseases. This review compares genetic diseases that result from defects in specific nucleotide salvage enzymes and a signaling kinase that activates nucleotide salvage after DNA damage exposure. These diseases include Lesch-Nyhan syndrome, mitochondrial depletion syndromes, and ataxia telangiectasia. Although treatment options are available to palliate symptoms of these diseases, there is no cure. The conclusions drawn from this review include the critical role of guanine nucleotides in preventing neurodegeneration, the limitations of animals as disease models, and the need to further understand nucleotide imbalances in treatment regimens. Such knowledge will hopefully guide future studies into clinical therapies for genetic diseases.
Collapse
Affiliation(s)
- Michael Fasullo
- Colleges of Nanoscale Sciences and Engineering, State University of New York Polytechnic University, Albany, NY 12203, USA.
| | - Lauren Endres
- Colleges of Nanoscale Sciences and Engineering, State University of New York Polytechnic University, Albany, NY 12203, USA.
| |
Collapse
|
11
|
Dauphinot L, Mockel L, Cahu J, Jinnah HA, Ledroit M, Potier MC, Ceballos-Picot I. Transcriptomic approach to Lesch-Nyhan disease. NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS 2015; 33:208-17. [PMID: 24940671 DOI: 10.1080/15257770.2014.880477] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
Lesch-Nyhan disease (LND) is an X-linked metabolic disease caused by various mutations in the gene HPRT1 encoding an enzyme of purine metabolism, hypoxanthine guanine phosphoribosyltransferase (HPRT). In its most severe form, LND patients suffer from overproduction of uric acid along with neurological or behavioural difficulties including self-injurious behaviours. To gain more insight into pathogenesis, we compared the transcriptome from human LND fibroblasts to normal human fibroblasts using a microarray with 60,000 probes corresponding to the entire human genome. Using stringent criteria, we identified 25 transcripts whose expression was significantly different between LND and control cells. These genes were confirmed by quantitative RT-PCR to be dysregulated in LND cells. Moreover, bioinformatic analysis of microarray data using gene ontology (GO) highlighted clusters of genes displaying biological processes most significantly affected in LND cells. These affected genes belonged to specific processes such as cell cycle and cell-division processes, metabolic and nucleic acid processes, demonstrating the specific nature of the changes and providing new insights into LND pathogenesis.
Collapse
Affiliation(s)
- Luce Dauphinot
- a CRICM, UPMC Hôpital de la Pitié-Salpêtrière , Paris , France
| | | | | | | | | | | | | |
Collapse
|
12
|
Bartolomé-Nebreda JM, Alonso de Diego SA, Artola M, Delgado F, Delgado Ó, Martín-Martín ML, Martínez-Viturro CM, Pena MÁ, Tong HM, Van Gool M, Alonso JM, Fontana A, Macdonald GJ, Megens A, Langlois X, Somers M, Vanhoof G, Conde-Ceide S. Identification of a Novel Orally Bioavailable Phosphodiesterase 10A (PDE10A) Inhibitor with Efficacy in Animal Models of Schizophrenia. J Med Chem 2015; 58:978-93. [DOI: 10.1021/jm501651a] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Affiliation(s)
- José Manuel Bartolomé-Nebreda
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Chemistry, Janssen Research & Development, Calle Jarama 75, Polígono Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Neuroscience Biology, ⊥Discovery Sciences ADME/Tox, and #Discovery Sciences Cellular Pharmacology, Janssen Research & Development, Turnhoutseweg 30, B-2340, Beerse, Belgium
| | - Sergio A. Alonso de Diego
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Chemistry, Janssen Research & Development, Calle Jarama 75, Polígono Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Neuroscience Biology, ⊥Discovery Sciences ADME/Tox, and #Discovery Sciences Cellular Pharmacology, Janssen Research & Development, Turnhoutseweg 30, B-2340, Beerse, Belgium
| | - Marta Artola
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Chemistry, Janssen Research & Development, Calle Jarama 75, Polígono Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Neuroscience Biology, ⊥Discovery Sciences ADME/Tox, and #Discovery Sciences Cellular Pharmacology, Janssen Research & Development, Turnhoutseweg 30, B-2340, Beerse, Belgium
| | - Francisca Delgado
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Chemistry, Janssen Research & Development, Calle Jarama 75, Polígono Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Neuroscience Biology, ⊥Discovery Sciences ADME/Tox, and #Discovery Sciences Cellular Pharmacology, Janssen Research & Development, Turnhoutseweg 30, B-2340, Beerse, Belgium
| | - Óscar Delgado
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Chemistry, Janssen Research & Development, Calle Jarama 75, Polígono Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Neuroscience Biology, ⊥Discovery Sciences ADME/Tox, and #Discovery Sciences Cellular Pharmacology, Janssen Research & Development, Turnhoutseweg 30, B-2340, Beerse, Belgium
| | - María Luz Martín-Martín
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Chemistry, Janssen Research & Development, Calle Jarama 75, Polígono Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Neuroscience Biology, ⊥Discovery Sciences ADME/Tox, and #Discovery Sciences Cellular Pharmacology, Janssen Research & Development, Turnhoutseweg 30, B-2340, Beerse, Belgium
| | - Carlos M. Martínez-Viturro
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Chemistry, Janssen Research & Development, Calle Jarama 75, Polígono Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Neuroscience Biology, ⊥Discovery Sciences ADME/Tox, and #Discovery Sciences Cellular Pharmacology, Janssen Research & Development, Turnhoutseweg 30, B-2340, Beerse, Belgium
| | - Miguel Ángel Pena
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Chemistry, Janssen Research & Development, Calle Jarama 75, Polígono Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Neuroscience Biology, ⊥Discovery Sciences ADME/Tox, and #Discovery Sciences Cellular Pharmacology, Janssen Research & Development, Turnhoutseweg 30, B-2340, Beerse, Belgium
| | - Han Min Tong
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Chemistry, Janssen Research & Development, Calle Jarama 75, Polígono Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Neuroscience Biology, ⊥Discovery Sciences ADME/Tox, and #Discovery Sciences Cellular Pharmacology, Janssen Research & Development, Turnhoutseweg 30, B-2340, Beerse, Belgium
| | - Michiel Van Gool
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Chemistry, Janssen Research & Development, Calle Jarama 75, Polígono Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Neuroscience Biology, ⊥Discovery Sciences ADME/Tox, and #Discovery Sciences Cellular Pharmacology, Janssen Research & Development, Turnhoutseweg 30, B-2340, Beerse, Belgium
| | - José Manuel Alonso
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Chemistry, Janssen Research & Development, Calle Jarama 75, Polígono Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Neuroscience Biology, ⊥Discovery Sciences ADME/Tox, and #Discovery Sciences Cellular Pharmacology, Janssen Research & Development, Turnhoutseweg 30, B-2340, Beerse, Belgium
| | - Alberto Fontana
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Chemistry, Janssen Research & Development, Calle Jarama 75, Polígono Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Neuroscience Biology, ⊥Discovery Sciences ADME/Tox, and #Discovery Sciences Cellular Pharmacology, Janssen Research & Development, Turnhoutseweg 30, B-2340, Beerse, Belgium
| | - Gregor J. Macdonald
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Chemistry, Janssen Research & Development, Calle Jarama 75, Polígono Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Neuroscience Biology, ⊥Discovery Sciences ADME/Tox, and #Discovery Sciences Cellular Pharmacology, Janssen Research & Development, Turnhoutseweg 30, B-2340, Beerse, Belgium
| | - Anton Megens
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Chemistry, Janssen Research & Development, Calle Jarama 75, Polígono Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Neuroscience Biology, ⊥Discovery Sciences ADME/Tox, and #Discovery Sciences Cellular Pharmacology, Janssen Research & Development, Turnhoutseweg 30, B-2340, Beerse, Belgium
| | - Xavier Langlois
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Chemistry, Janssen Research & Development, Calle Jarama 75, Polígono Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Neuroscience Biology, ⊥Discovery Sciences ADME/Tox, and #Discovery Sciences Cellular Pharmacology, Janssen Research & Development, Turnhoutseweg 30, B-2340, Beerse, Belgium
| | - Marijke Somers
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Chemistry, Janssen Research & Development, Calle Jarama 75, Polígono Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Neuroscience Biology, ⊥Discovery Sciences ADME/Tox, and #Discovery Sciences Cellular Pharmacology, Janssen Research & Development, Turnhoutseweg 30, B-2340, Beerse, Belgium
| | - Greet Vanhoof
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Chemistry, Janssen Research & Development, Calle Jarama 75, Polígono Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Neuroscience Biology, ⊥Discovery Sciences ADME/Tox, and #Discovery Sciences Cellular Pharmacology, Janssen Research & Development, Turnhoutseweg 30, B-2340, Beerse, Belgium
| | - Susana Conde-Ceide
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Chemistry, Janssen Research & Development, Calle Jarama 75, Polígono Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Neuroscience Biology, ⊥Discovery Sciences ADME/Tox, and #Discovery Sciences Cellular Pharmacology, Janssen Research & Development, Turnhoutseweg 30, B-2340, Beerse, Belgium
| |
Collapse
|
13
|
Construction of human LRIG1-TAT fusions and TAT-mediated LRIG1 protein delivery. Biomed Pharmacother 2014; 69:396-401. [PMID: 25661388 DOI: 10.1016/j.biopha.2014.12.034] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2014] [Accepted: 12/10/2014] [Indexed: 11/23/2022] Open
Abstract
Human leucine-rich repeats and immunoglobulin-like domains (LRIG1) is a tumor suppressor in animals and also functions as an endogenous suppressor in human tumor. The level of LRIG1 expression is highly associated with patient survival in clinic. The exploration of LRIG1 as a protein drug is an important task. HIV-1 transactivator of transcription peptide (TAT) is an excellent candidate for protein transduction. In this study, human LRIG1 was cloned and LRIG1-TAT fusion gene was constructed. The fusion proteins were produced by an Escherichia coli strain and purified by Ni(2+)-resin. Western blot assay and immunofluorescence microscopy were employed for monitoring LRIG1-TAT protein transduction into human neuroblastoma cells. Cell proliferation and invasion were measured for evaluating the effect of LRIG1-TAT on neuroblastoma cell. Our data showed that LRIG1 protein can be delivered into cells or organs in living animals by TAT. One-time transduction of LRIG1 proteins into human neuroblastoma cells enhanced cell proliferation and increased cell invasion. In vivo transduction showed that LRIG1-TAT protein can be presented in living animal organs. Our experiments provide a new vision on LRIG1 applications and also offer a therapy window for revealing the intrinsic function of LRIG1 on cells.
Collapse
|
14
|
Bartolomé-Nebreda JM, Delgado F, Martín-Martín ML, Martínez-Viturro CM, Pastor J, Tong HM, Iturrino L, Macdonald GJ, Sanderson W, Megens A, Langlois X, Somers M, Vanhoof G, Conde-Ceide S. Discovery of a Potent, Selective, and Orally Active Phosphodiesterase 10A Inhibitor for the Potential Treatment of Schizophrenia. J Med Chem 2014; 57:4196-212. [DOI: 10.1021/jm500073h] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Affiliation(s)
- José Manuel Bartolomé-Nebreda
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Sciences, Janssen Research & Development, Calle Jarama 75, Polígono
Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Discovery Sciences
Molecular Informatics, ⊥Neuroscience Biology, #Discovery Sciences ADME/Tox, and ∇Discovery Sciences
Translational Sciences, Janssen Research & Development, Turnhoutseweg
30, B-2340, Beerse, Belgium
| | - Francisca Delgado
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Sciences, Janssen Research & Development, Calle Jarama 75, Polígono
Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Discovery Sciences
Molecular Informatics, ⊥Neuroscience Biology, #Discovery Sciences ADME/Tox, and ∇Discovery Sciences
Translational Sciences, Janssen Research & Development, Turnhoutseweg
30, B-2340, Beerse, Belgium
| | - María Luz Martín-Martín
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Sciences, Janssen Research & Development, Calle Jarama 75, Polígono
Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Discovery Sciences
Molecular Informatics, ⊥Neuroscience Biology, #Discovery Sciences ADME/Tox, and ∇Discovery Sciences
Translational Sciences, Janssen Research & Development, Turnhoutseweg
30, B-2340, Beerse, Belgium
| | - Carlos M. Martínez-Viturro
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Sciences, Janssen Research & Development, Calle Jarama 75, Polígono
Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Discovery Sciences
Molecular Informatics, ⊥Neuroscience Biology, #Discovery Sciences ADME/Tox, and ∇Discovery Sciences
Translational Sciences, Janssen Research & Development, Turnhoutseweg
30, B-2340, Beerse, Belgium
| | - Joaquín Pastor
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Sciences, Janssen Research & Development, Calle Jarama 75, Polígono
Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Discovery Sciences
Molecular Informatics, ⊥Neuroscience Biology, #Discovery Sciences ADME/Tox, and ∇Discovery Sciences
Translational Sciences, Janssen Research & Development, Turnhoutseweg
30, B-2340, Beerse, Belgium
| | - Han Min Tong
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Sciences, Janssen Research & Development, Calle Jarama 75, Polígono
Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Discovery Sciences
Molecular Informatics, ⊥Neuroscience Biology, #Discovery Sciences ADME/Tox, and ∇Discovery Sciences
Translational Sciences, Janssen Research & Development, Turnhoutseweg
30, B-2340, Beerse, Belgium
| | - Laura Iturrino
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Sciences, Janssen Research & Development, Calle Jarama 75, Polígono
Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Discovery Sciences
Molecular Informatics, ⊥Neuroscience Biology, #Discovery Sciences ADME/Tox, and ∇Discovery Sciences
Translational Sciences, Janssen Research & Development, Turnhoutseweg
30, B-2340, Beerse, Belgium
| | - Gregor J. Macdonald
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Sciences, Janssen Research & Development, Calle Jarama 75, Polígono
Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Discovery Sciences
Molecular Informatics, ⊥Neuroscience Biology, #Discovery Sciences ADME/Tox, and ∇Discovery Sciences
Translational Sciences, Janssen Research & Development, Turnhoutseweg
30, B-2340, Beerse, Belgium
| | - Wendy Sanderson
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Sciences, Janssen Research & Development, Calle Jarama 75, Polígono
Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Discovery Sciences
Molecular Informatics, ⊥Neuroscience Biology, #Discovery Sciences ADME/Tox, and ∇Discovery Sciences
Translational Sciences, Janssen Research & Development, Turnhoutseweg
30, B-2340, Beerse, Belgium
| | - Anton Megens
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Sciences, Janssen Research & Development, Calle Jarama 75, Polígono
Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Discovery Sciences
Molecular Informatics, ⊥Neuroscience Biology, #Discovery Sciences ADME/Tox, and ∇Discovery Sciences
Translational Sciences, Janssen Research & Development, Turnhoutseweg
30, B-2340, Beerse, Belgium
| | - Xavier Langlois
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Sciences, Janssen Research & Development, Calle Jarama 75, Polígono
Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Discovery Sciences
Molecular Informatics, ⊥Neuroscience Biology, #Discovery Sciences ADME/Tox, and ∇Discovery Sciences
Translational Sciences, Janssen Research & Development, Turnhoutseweg
30, B-2340, Beerse, Belgium
| | - Marijke Somers
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Sciences, Janssen Research & Development, Calle Jarama 75, Polígono
Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Discovery Sciences
Molecular Informatics, ⊥Neuroscience Biology, #Discovery Sciences ADME/Tox, and ∇Discovery Sciences
Translational Sciences, Janssen Research & Development, Turnhoutseweg
30, B-2340, Beerse, Belgium
| | - Greet Vanhoof
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Sciences, Janssen Research & Development, Calle Jarama 75, Polígono
Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Discovery Sciences
Molecular Informatics, ⊥Neuroscience Biology, #Discovery Sciences ADME/Tox, and ∇Discovery Sciences
Translational Sciences, Janssen Research & Development, Turnhoutseweg
30, B-2340, Beerse, Belgium
| | - Susana Conde-Ceide
- Neuroscience Medicinal Chemistry and ‡Discovery Sciences Analytical Sciences, Janssen Research & Development, Calle Jarama 75, Polígono
Industrial, Toledo 45007, Spain
- Neuroscience Medicinal Chemistry, ∥Discovery Sciences
Molecular Informatics, ⊥Neuroscience Biology, #Discovery Sciences ADME/Tox, and ∇Discovery Sciences
Translational Sciences, Janssen Research & Development, Turnhoutseweg
30, B-2340, Beerse, Belgium
| |
Collapse
|
15
|
Striatal neurodevelopment is dysregulated in purine metabolism deficiency and impacts DARPP-32, BDNF/TrkB expression and signaling: new insights on the molecular and cellular basis of Lesch-Nyhan Syndrome. PLoS One 2014; 9:e96575. [PMID: 24804781 PMCID: PMC4013014 DOI: 10.1371/journal.pone.0096575] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2014] [Accepted: 04/08/2014] [Indexed: 01/19/2023] Open
Abstract
Lesch-Nyhan Syndrome (LNS) is a neurodevelopmental disorder caused by mutations in the gene encoding the purine metabolic enzyme hypoxanthine-guanine phosphoribosyltransferase (HPRT). This syndrome is characterized by an array of severe neurological impairments that in part originate from striatal dysfunctions. However, the molecular and cellular mechanisms underlying these dysfunctions remain largely unidentified. In this report, we demonstrate that HPRT-deficiency causes dysregulated expression of key genes essential for striatal patterning, most notably the striatally-enriched transcription factor B-cell leukemia 11b (Bcl11b). The data also reveal that the down-regulated expression of Bcl11b in HPRT-deficient immortalized mouse striatal (STHdh) neural stem cells is accompanied by aberrant expression of some of its transcriptional partners and other striatally-enriched genes, including the gene encoding dopamine- and cAMP-regulated phosphoprotein 32, (DARPP-32). Furthermore, we demonstrate that components of the BDNF/TrkB signaling, a known activator of DARPP-32 striatal expression and effector of Bcl11b transcriptional activation are markedly increased in HPRT-deficient cells and in the striatum of HPRT knockout mouse. Consequently, the HPRT-deficient cells display superior protection against reactive oxygen species (ROS)-mediated cell death upon exposure to hydrogen peroxide. These findings suggest that the purine metabolic defect caused by HPRT-deficiency, while it may provide neuroprotection to striatal neurons, affects key genes and signaling pathways that may underlie the neuropathogenesis of LNS.
Collapse
|
16
|
Cattelan P, Dolcetta D, Hladnik U, Fortunati E. HIV-1 TAT-mediated protein transduction of human HPRT into deficient cells. Biochem Biophys Res Commun 2013; 441:114-9. [PMID: 24129187 DOI: 10.1016/j.bbrc.2013.10.029] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2013] [Accepted: 10/07/2013] [Indexed: 11/19/2022]
Abstract
Lesch-Nyhan disease (LND) is a severe and incurable X-linked genetic syndrome caused by the deficiency of hypoxanthine-guanine phosphoribosyltransferase (HPRT), resulting in severe alterations of central nervous system, hyperuricemia and subsequent impaired renal functions. Therapeutic options consist in supportive care and treatments of complications, but the disease remains largely untreatable. Enzyme replacement of the malfunctioning cytosolic protein might represent a possible therapeutic approach for the LND treatment. Protein transduction domains, such as the TAT peptide derived from HIV TAT protein, have been used to transduce macromolecules into cells in vitro and in vivo. The present study was aimed to the generation of TAT peptide fused to human HPRT for cell transduction in enzyme deficient cells. Here we document the construction, expression and delivery of a functional HPRT enzyme into deficient cells by TAT transduction domain and by liposome mediated protein transfer. With this approach we demonstrate the correction of the enzymatic defect in HPRT deficient cells. Our data show for the first time the feasibility of the enzyme replacement therapy for the treatment of LND.
Collapse
Affiliation(s)
- Paola Cattelan
- 'Mauro Baschirotto' Institute for Rare Diseases-B.I.R.D., 36023 Costozza di Longare, Vicenza, Italy
| | | | | | | |
Collapse
|
17
|
Guibinga GH, Murray F, Barron N, Pandori W, Hrustanovic G. Deficiency of the purine metabolic gene HPRT dysregulates microRNA-17 family cluster and guanine-based cellular functions: a role for EPAC in Lesch-Nyhan syndrome. Hum Mol Genet 2013; 22:4502-15. [PMID: 23804752 DOI: 10.1093/hmg/ddt298] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
Lesch-Nyhan syndrome (LNS) is a neurodevelopmental disorder caused by mutations in the gene encoding the purine metabolic enzyme hypoxanthine-guanine phosphoribosyltransferase (HPRT). A series of motor, cognitive and neurobehavioral anomalies characterize this disease phenotype, which is still poorly understood. The clinical manifestations of this syndrome are believed to be the consequences of deficiencies in neurodevelopmental pathways that lead to disordered brain function. We have used microRNA array and gene ontology analysis to evaluate the gene expression of differentiating HPRT-deficient human neuron-like cell lines. We set out to identify dysregulated genes implicated in purine-based cellular functions. Our approach was based on the premise that HPRT deficiency affects preeminently the expression and the function of purine-based molecular complexes, such as guanine nucleotide exchange factors (GEFs) and small GTPases. We found that several microRNAs from the miR-17 family cluster and genes encoding GEF are dysregulated in HPRT deficiency. Most notably, our data show that the expression of the exchange protein activated by cAMP (EPAC) is blunted in HPRT-deficient human neuron-like cell lines and fibroblast cells from LNS patients, and is altered in the cortex, striatum and midbrain of HPRT knockout mouse. We also show a marked impairment in the activation of small GTPase RAP1 in the HPRT-deficient cells, as well as differences in cytoskeleton dynamics that lead to increased motility for HPRT-deficient neuron-like cell lines relative to control. We propose that the alterations in EPAC/RAP1 signaling and cell migration in HPRT deficiency are crucial for neuro-developmental events that may contribute to the neurological dysfunctions in LNS.
Collapse
|